Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,591.90
(
0.54%
)
US TECH 100
23,454.40
(
0.41%
)
Dow Jones
46,429.49
(
0.66%
)
Brent Oil
98.87
(
0.09%
)
Bitcoin
71,192.00
(
-0.16%
)
News Focus
News Focus
Post# of 257287
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122810
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 48757

Wednesday, 06/20/2007 4:54:01 PM

Wednesday, June 20, 2007 4:54:01 PM

Post# of 257287
COLY – The wording of today’s PR (#msg-20613423) and the comments on today’s CC leave the door open a crack for PFE to continue the phase-2 trial testing PF-3512676 with Tarceva in second-line NSCLC. PFE may still be deciding what to do about this trial, which does not employ chemotherapy and hence has a somewhat different risk/benefit tradeoff than all of the other PF-3512676 trials in NSCLC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up